On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant

  • Producing cannabinoids through biosynthesis
  • CANNSYNTHESIS® platform has capacity to scale up
  • Revenues from out-licensing technology

For the half a billion or so who suffer from one type or another of diabetes, biosynthesis offers a lifeline. For it is through biosynthesis that much of the world’s insulin is produced. Insulin regulates the metamorphosis of fats and protein and, importantly, allows the cells in the muscles, fat and liver to absorb glucose from the blood. When the body does not produce enough insulin nor use the insulin it produces efficiently, blood sugar levels may rise dangerously. However, biosynthesis, a mid-twentieth century technology, is not employed solely in producing insulin but finds application in many other fields. For example, Teewinot Life Sciences Corporation uses biosynthesis to produce cannabinoids, a method of manufacture that is much less costly than growing cannabis plants and extracting the cannabinoids. With biosynthesis, Teewinot Life Sciences is able to produce cannabinoids without touching the cannabis plant.

Despite changing attitudes, cannabis remains a prohibited or controlled substance in many jurisdictions worldwide. In the U.S., for example, it is regulated pursuant to the Controlled Substances Act of 1970, under which authorities have classified marijuana as a Schedule I drug, alongside heroin and LSD. By so doing, all cannabinoids risk being tainted with illegality if they are extracted from the marijuana plant. However, most cannabinoids produced biosynthetically may escape the prohibitions of the CSA, since only THC is specifically mentioned in Schedule I.

Teewinot manufactures cannabinoids that have the same chemical structure as naturally-occurring phytocannabinoids by means of its patent-protected methods. These proprietary methods of manufacturing cannabinoids are less expensive than growing cannabis plants and extracting the cannabinoids. Moreover, the technology can be used to cost-effectively manufacture cannabinoid pro-drugs and cannabinoid analogs that do not naturally occur in the cannabis plant. A pro-drug is a substance that is metabolized by the body into a pharmacologically-active agent. Perhaps the best known pro-drug is paracetamol (acetaminophen), which is now thought to exert its analgesic (and probably anti-pyretic) effects by metamorphosizing into an anandamide, an endocannabinoid. In very general terms, this means that in the human body, paracetamol degrades to a cannabimimetic, or a substance that mimics a cannabinoid.

Developed by its labs in Vancouver, British Columbia, and Steinbach, Manitoba, this groundbreaking biosynthesis technology has long outgrown its micro environment. Teewinot Life Sciences has developed CannSynthesis™ to be employed for the large-scale manufacture of pharmaceutically pure cannabinoids. The technology has been licensed for the commercial production of the first analytical standard of CBCA (cannabichromenic acid) and for the manufacture of a patent-protected pro-drug of a cannabinoid. Teewinot’s cannabinoid pro-drugs are designed to be more bioavailable and stable in the human body, thereby increasing their efficacy.

Apart from THC and CBD, many of the 111 or so cannabinoids found in the cannabis plant are produced in minute quantities. Production by extraction is thus prohibitively costly, meaning that most cannabinoids have not been available for research and therapeutic applications. The CANNSYNTHESIS® platform has changed that paradigm, however, since it allows for the efficient production of cannabinoids in kilogram quantities. Teewinot’s CANNSYNTHESIS® has taken the production of cannabinoids from the lab to clinical settings, since the technology can deliver consistent and controlled dosages. Buoyed by its successes, the company continues to work with leading universities and pharmaceutical companies to provide novel patient therapies.

For more information, visit the company’s website at www.TLSCorp.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

Contact us: 212.418.1217